Patient characteristics
| Characteristic . | Feature . | Total . | ATAC-seq . | RNA-seq . | TCR-seq . |
|---|---|---|---|---|---|
| N = 88 . | n = 7 . | n = 4 . | n = 5 . | ||
| Age | Median (range) | 53 (19-72) | 42 (19-73) | 50 (37-66) | 37 (33-66) |
| Sex | Male (%) | 56 (64) | 5 (71) | 4 (100) | 4 (80) |
| Female (%) | 32 (36) | 2 (29) | 0 | 1 (20) | |
| Disease | AML (%) | 35 (40) | 2 (29) | 2 (50) | 3 (60) |
| MDS (%) | 21 (24) | 1 (14) | 0 | 0 | |
| CML (%) | 3 (3) | 0 | 0 | 0 | |
| Myelofibrosis (%) | 1 (1) | 0 | 1 (25) | 0 | |
| ALL (%) | 9 (10) | 3 (43) | 0 | 2 (40) | |
| NHL (%) | 13 (15) | 1 (14) | 1 (25) | 0 | |
| HL (%) | 4 (5) | 0 | 0 | 0 | |
| CLL (%) | 1 (1) | 0 | 0 | 0 | |
| T-PLL (%) | 1 (1) | 0 | 0 | 0 | |
| D+/R+ (%) | 32 (36) | 2 (29) | 3 (75) | 1 (20) | |
| D+/R– (%) | 3 (3) | 0 | 0 | 0 | |
| D–/R+ (%) | 21 (24) | 3 (43) | 0 | 3 (60) | |
| CMV | D–/R– (%) | 32 (36) | 2 (29) | 1 (25) | 1 (20) |
| Reactivation (%) | 21 (24) | 0 | 0 | 1 (20) | |
| EBV | Reactivation (%) | 9 (10) | 1 (14) | 1 (25) | 1 (20) |
| Conditioning | Cy/TBI (%) | 10 (11) | 3 (43) | 0 | 2 (40) |
| Flu/Bu/ATG (%) | 18 (21) | 1 (14) | 3 (75) | 2 (40) | |
| Flu/Mel/Campath (%) | 33 (38) | 2 (29) | 0 | 0 | |
| Flu/Bu/Camptah (%) | 1 (1) | 0 | 0 | 0 | |
| Bu/Cy (%) | 3 (3) | 1 (14) | 0 | 1 (20) | |
| BEAM/Campath (%) | 8 (9) | 0 | 1 (25) | 0 | |
| Flu/Cy/TBI (%) | 5 (6) | 0 | 0 | 0 | |
| FLAMSA/Bu (%) | 10 (11) | 0 | 0 | 0 | |
| GVHD prophylaxis | Ciclosporin only (%) | 58 (66) | 4 (57) | 4 (100) | 2 (40) |
| Ciclosporin + methotrexate (%) | 15 (17) | 3 (43) | 0 | 3 (60) | |
| Ciclosporin + MMF (%) | 15 (17) | 0 | 0 | 0 | |
| Source of graft | PBSC (%) | 83 (94) | 6 (86) | 4 (100) | 3 (60) |
| BM (%) | 3 (3) | 1 (14) | 0 | 2 (40) | |
| Cord (%) | 2 (2) | 0 | 0 | 0 | |
| Type | MUD (%) | 62 (71) | 5 (71) | 3 (75) | 3 (60) |
| MRD (%) | 23 (26) | 2 (29) | 1 (25) | 2 (40) | |
| Cord (%) | 3 (3) | 0 | 0 | 0 | |
| GVHD | Acute (2-4) (%) | 31 (35) | 7 (100) | 4 (100) | 5 (100) |
| Chronic (%) | 9 (10) | 1 (14) | 0 | 0 | |
| Median day of onset | +50 | +98 | +117 | +70 | |
| Relapse (%) | 13 (15) | 0 | 1 (25) | 0 |
| Characteristic . | Feature . | Total . | ATAC-seq . | RNA-seq . | TCR-seq . |
|---|---|---|---|---|---|
| N = 88 . | n = 7 . | n = 4 . | n = 5 . | ||
| Age | Median (range) | 53 (19-72) | 42 (19-73) | 50 (37-66) | 37 (33-66) |
| Sex | Male (%) | 56 (64) | 5 (71) | 4 (100) | 4 (80) |
| Female (%) | 32 (36) | 2 (29) | 0 | 1 (20) | |
| Disease | AML (%) | 35 (40) | 2 (29) | 2 (50) | 3 (60) |
| MDS (%) | 21 (24) | 1 (14) | 0 | 0 | |
| CML (%) | 3 (3) | 0 | 0 | 0 | |
| Myelofibrosis (%) | 1 (1) | 0 | 1 (25) | 0 | |
| ALL (%) | 9 (10) | 3 (43) | 0 | 2 (40) | |
| NHL (%) | 13 (15) | 1 (14) | 1 (25) | 0 | |
| HL (%) | 4 (5) | 0 | 0 | 0 | |
| CLL (%) | 1 (1) | 0 | 0 | 0 | |
| T-PLL (%) | 1 (1) | 0 | 0 | 0 | |
| D+/R+ (%) | 32 (36) | 2 (29) | 3 (75) | 1 (20) | |
| D+/R– (%) | 3 (3) | 0 | 0 | 0 | |
| D–/R+ (%) | 21 (24) | 3 (43) | 0 | 3 (60) | |
| CMV | D–/R– (%) | 32 (36) | 2 (29) | 1 (25) | 1 (20) |
| Reactivation (%) | 21 (24) | 0 | 0 | 1 (20) | |
| EBV | Reactivation (%) | 9 (10) | 1 (14) | 1 (25) | 1 (20) |
| Conditioning | Cy/TBI (%) | 10 (11) | 3 (43) | 0 | 2 (40) |
| Flu/Bu/ATG (%) | 18 (21) | 1 (14) | 3 (75) | 2 (40) | |
| Flu/Mel/Campath (%) | 33 (38) | 2 (29) | 0 | 0 | |
| Flu/Bu/Camptah (%) | 1 (1) | 0 | 0 | 0 | |
| Bu/Cy (%) | 3 (3) | 1 (14) | 0 | 1 (20) | |
| BEAM/Campath (%) | 8 (9) | 0 | 1 (25) | 0 | |
| Flu/Cy/TBI (%) | 5 (6) | 0 | 0 | 0 | |
| FLAMSA/Bu (%) | 10 (11) | 0 | 0 | 0 | |
| GVHD prophylaxis | Ciclosporin only (%) | 58 (66) | 4 (57) | 4 (100) | 2 (40) |
| Ciclosporin + methotrexate (%) | 15 (17) | 3 (43) | 0 | 3 (60) | |
| Ciclosporin + MMF (%) | 15 (17) | 0 | 0 | 0 | |
| Source of graft | PBSC (%) | 83 (94) | 6 (86) | 4 (100) | 3 (60) |
| BM (%) | 3 (3) | 1 (14) | 0 | 2 (40) | |
| Cord (%) | 2 (2) | 0 | 0 | 0 | |
| Type | MUD (%) | 62 (71) | 5 (71) | 3 (75) | 3 (60) |
| MRD (%) | 23 (26) | 2 (29) | 1 (25) | 2 (40) | |
| Cord (%) | 3 (3) | 0 | 0 | 0 | |
| GVHD | Acute (2-4) (%) | 31 (35) | 7 (100) | 4 (100) | 5 (100) |
| Chronic (%) | 9 (10) | 1 (14) | 0 | 0 | |
| Median day of onset | +50 | +98 | +117 | +70 | |
| Relapse (%) | 13 (15) | 0 | 1 (25) | 0 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; BEAM, BCNU, etoposide, cytarabine and melphalan; BM, bone marrow; Bu, Busulfan; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; Cy, cyclophosphamide; D, donor; EBV, Epstein-Barr virus; FLAMSA, fludarabine, amsacrine, and cytarabine; Flu, fludarabine; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; Mel, melphalan; MMF, mycophenolate mofetil; MRD, measurable (or minimal) residual disease; MUD, matched unrelated donor; NHL, non-Hodgkin lymphoma; PBSC, peripheral blood stem cells; R, recepient; TBI, total body irradiation.